mPGES-1/EP1 in volume regulation
mPGES-1/EP1 在音量调节中的作用
基本信息
- 批准号:8398952
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAldosteroneAnalgesicsAnti-Inflammatory AgentsAnti-inflammatoryAttentionAttenuatedBlood PressureCardiovascular systemCouplesDinoprostoneDistalDiureticsEdemaEnzymesEquilibriumExcretory functionExhibitsExtracellular FluidHandHypernatremiaHypertensionInflammationInflammatory ResponseInfusion proceduresIntakeInvestigationIsomeraseKidneyLightLiquid substanceMarketingMediatingMolecularMolecular TargetMusNatriuresisPTGS2 genePainPathway interactionsPerfusionPharmaceutical PreparationsPhenotypePhysiologicalPhysiological ProcessesPlayProcessProductionPropertyProstaglandin-Endoperoxide SynthaseProstaglandinsPublishingRegulationRenal functionRenal tubule structureRoleSafetySiteSodium ChlorideSteroidsTherapeuticToxic effectTubular formationWaterin vivoinhibitor/antagonistkidney cellnext generationnovelpressureprostaglandin E synthase-1prostanoid receptor EP1responsesalureticurinary
项目摘要
DESCRIPTION (provided by applicant):
Summary: The kidney plays a major role in the regulation of extracellular fluid volume (ECFV) and blood + + pressure (BP) via adjustment of urinary Na excretion in alignment with Na intake. Despite intensive + investigation, the molecular mechanism of renal handing of Na and water balance is still imperfectly understood. A large body of evidence demonstrates that PGE2 is an important regulator of renal function + due to its natriuretic and diuretic properties. In isolated microperfused renal tubules, PGE2 inhibits Na and water transport. Moreover, the inhibition of prostanoid synthesis with Non-Steroid Anti-inflammatory Drugs (NSAIDs) or COX-2 inhibitors is associated with cardiovascular consequences, including hypertension and edema formation. Microsomal prostaglandin E synthase-1 (mPGES-1) has been characterized as the only isomerase processing the in vivo PGES activity and is critically involved in the pain and inflammatory responses. In recent years, mPGES-1 has received a great attention due to the promise for serving as a novel target for anti-inflammatory drugs. The lesson from COX-2 inhibitors has prompted a thorough examination of the role of mPGES-1 in physiological processes. Our published studies demonstrate that mPGES-1 KO mice exhibit impaired natriuretic/diuretic responses to salt loading and also fail to undergo aldosterone (Aldo) escape. The phenotype was recapitulated by EP1 antagonism. We hypothesize that renal mPGES-1/ EP1 pathway responds to a rise in renal perfusion pressure (RPP) + during ECFV expansion and elicits natriuresis through inhibition of renal Na transport thereby + attenuating Na retention and hypertension. We propose to define the role of mPGES-1- and EP1 receptors under two different volume expansion states induced by Aldo infusion and high salt loading. Major experimental approaches involve the production and analysis of mice with renal cell-deletion of mPGES-1 and EP1 as well as the examination of RPP as a regulator of renal PGE2 synthesis. There are 3 specific aims: 1) to investigate the influence of systemic mPGES-1 deletion on volume regulation, 2) to investigate the influence of site-specific mPGES-1 inhibition on volume regulation, and 3) to investigate the role of EP1 in volume regulation. New information resulted from this proposal will help define PGE cascades in the control of ECFV.
描述(由申请人提供):
总结:肾脏通过调整尿钠排泄与钠摄入量,在细胞外液容量(ECFV)和血压(BP)的调节中起主要作用。尽管进行了深入的研究,但肾脏处理钠和水平衡的分子机制仍不完全清楚。大量证据表明,PGE 2是肾功能的重要调节剂+,因为它具有利钠和利尿特性。在离体微灌注肾小管中,PGE 2抑制Na和水的转运。此外,用非甾体抗炎药(NSAID)或考克斯-2抑制剂抑制前列腺素类合成与心血管后果相关,包括高血压和水肿形成。微粒体前列腺素E合酶-1(mPGES-1)是唯一的体内异构酶,参与疼痛和炎症反应。近年来,mPGES-1由于有望作为抗炎药物的新靶点而受到极大关注。从考克斯-2抑制剂的教训,促使mPGES-1在生理过程中的作用进行了彻底的检查。我们发表的研究表明,mPGES-1 KO小鼠表现出受损的钠尿/利尿反应盐负荷,也未能进行醛固酮(Aldo)逃逸。表型通过EP 1拮抗作用重现。我们推测,肾mPGES-1/EP 1途径通过抑制肾Na转运,从而减轻Na+潴留和高血压,对ECFV扩张期间肾灌注压(RPP)+的升高做出反应。我们建议定义mPGES-1-和EP 1受体的作用下两个不同的体积膨胀状态诱导的阿尔多输液和高盐负荷。主要的实验方法包括生产和分析mPGES-1和EP 1肾细胞缺失的小鼠,以及检查RPP作为肾脏PGE 2合成的调节剂。有三个具体目标:1)研究系统性mPGES-1缺失对容量调节的影响,2)研究位点特异性mPGES-1抑制对容量调节的影响,3)研究EP 1在容量调节中的作用。新的信息,从这个建议将有助于确定铂族元素级联的控制ECFV。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tianxin Yang其他文献
Tianxin Yang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tianxin Yang', 18)}}的其他基金
Adipose-derived sPRR controls circadian rhythm of blood pressure through inhibition of renal NCC activity
脂肪源性 sPRR 通过抑制肾 NCC 活性来控制血压的昼夜节律
- 批准号:
10522511 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Adipose-derived sPRR controls circadian rhythm of blood pressure through inhibition of renal NCC activity
脂肪源性 sPRR 通过抑制肾 NCC 活性来控制血压的昼夜节律
- 批准号:
10636885 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Defining renal S1P/sPRR/AT1R pathway in salt-sensitive hypertension
盐敏感性高血压肾 S1P/sPRR/AT1R 通路的定义
- 批准号:
10293534 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Defining renal S1P/sPRR/AT1R pathway in salt-sensitive hypertension
盐敏感性高血压肾 S1P/sPRR/AT1R 通路的定义
- 批准号:
10514577 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Defining renal S1P/sPRR/AT1R pathway in salt-sensitive hypertension
盐敏感性高血压肾 S1P/sPRR/AT1R 通路的定义
- 批准号:
9888044 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Role of (pro)renin receptor in aldosterone signaling in the kidney
肾素(原)受体在肾脏醛固酮信号传导中的作用
- 批准号:
9921471 - 财政年份:2018
- 资助金额:
-- - 项目类别:
相似海外基金
In vivo and ex vivo lessons from somatic adrenal mutations in cell adhesion molecule 1 for physiological and pathological production of aldosterone
细胞粘附分子 1 体细胞肾上腺突变对醛固酮生理和病理产生的体内和离体教训
- 批准号:
MR/X018970/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Fellowship
Creating therapeutic strategies targeting both aldosterone and AGEs-RAGE axis for stopping kidney diseases progression
制定针对醛固酮和 AGEs-RAGE 轴的治疗策略,以阻止肾脏疾病的进展
- 批准号:
23K15240 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Processivity and Catalytic Mechanism of Aldosterone Synthase
醛固酮合酶的持续合成能力和催化机制
- 批准号:
10600520 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Aldosterone/mineralocorticoid receptor responses to biologic sex and salt intake: Role of Lysine Specific Demethylase 1 (LSD1)
醛固酮/盐皮质激素受体对生物性别和盐摄入量的反应:赖氨酸特异性脱甲基酶 1 (LSD1) 的作用
- 批准号:
10930190 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of a CYP11B2 probe for imaging aldosterone-producing adenomas with high sensitivity.
开发用于高灵敏度对产生醛固酮的腺瘤进行成像的 CYP11B2 探针。
- 批准号:
23H02850 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension
醛固酮阻断用于终末期肾病健康改善评估:延伸
- 批准号:
461992 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Operating Grants
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
利钠肽-肾素-血管紧张素-醛固酮系统节律轴与夜间血压
- 批准号:
10545747 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
利钠肽-肾素-血管紧张素-醛固酮系统节律轴与夜间血压
- 批准号:
10342142 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Role of Renin-Angiotensin-Aldosterone System during sarcoidosis granuloma formation
肾素-血管紧张素-醛固酮系统在结节病肉芽肿形成过程中的作用
- 批准号:
10591934 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Association between excessive salt intake and brain renin-angiotensin-aldosterone system in obesity.
肥胖中过量盐摄入与脑肾素-血管紧张素-醛固酮系统之间的关联。
- 批准号:
22K08167 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




